Nautilus Biotechnolgy, Inc. (NAUT) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nautilus Biotechnology, Inc. faces a significant risk of its Common Stock being delisted from Nasdaq due to non-compliance with the Minimum Bid Price Requirement. This situation could adversely affect the company’s ability to sell equity securities and the liquidity of its stock. Despite efforts to transfer its listing to the Nasdaq Capital Market and potentially conduct a reverse stock split, there is no assurance of regaining compliance. Delisting could lead to reduced market quotations, liquidity, and trading activity, as well as hinder future financing opportunities.
Overall, Wall Street has a Moderate Buy consensus rating on NAUT stock based on 2 Buys.
To learn more about Nautilus Biotechnolgy, Inc.’s risk factors, click here.